No need of prescription from Doctors for Refresh Tears: DTAB
New Delhi: Granting drug maker Allergan India request to change the category of "Refresh Tears" from prescription drug to over the counter drug, the Drug Technical Advisory Board (DTAB) has agreed to remove the requirement of a prescription from a Registered Medical Practitioner (RMP) in respect of drug product "Refresh Tears" (Carboxymethylcellulose Sodium eye drops IP 0.5% w/v) for its retail sale.
The recommendation was made after considering the proposal made by Allergan India to remove the requirement for a prescription in respect of drug product "Refresh Tears" (Carboxymethylcellulose Sodium eye drops IP 0.5% w/v) sterile opthalmic solution for retail sale.
Also Read:59 drug samples including Cadila Pharma Aciloc 150 fail to qualify CDSCO test
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.